2616 — CStone Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- HK$1.09bn
- HK$374.00m
- CNY463.84m
Annual income statement for CStone Pharmaceuticals, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 1,039 | 244 | 481 | 464 |
| Cost of Revenue | |||||
| Gross Profit | — | 797 | 137 | 278 | 304 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2,308 | 2,259 | 2,162 | 1,376 | 819 |
| Operating Profit | -2,308 | -1,220 | -1,918 | -894 | -355 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -2,308 | -1,221 | -1,920 | -903 | -367 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2,308 | -1,221 | -1,920 | -903 | -367 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -2,308 | -1,221 | -1,920 | -903 | -367 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2,069 | -1,221 | -1,920 | -903 | -367 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.37 | -1.17 | -1.65 | -0.75 | -0.411 |